Tricyclic pyrone analogs: A new class of microtubule-disrupting anticancer drugs effective against murine leukemia cells in vitro

International Journal of Oncology

Volumn 12, Issue 2, 1998, Pages 433-442

  Newell, Steven W ^a   Perchellet, Elisabeth M ^a   Ladesich, James B ^a   Freeman, Jonathan A ^a   Chen, Yi ^b   Liu, Lanzhen ^b   Hua, Duy H ^b   Kraft, Susan L ^b   Basaraba, Randall J ^b   Perchellet, Jean Pierre ^a,b  

^a Div of Biology   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

L1210 cells; Macromolecule synthesis; Tricyclic pyrones; Tubulin polymerization; Tumor cell growth

Indexed keywords

ANTINEOPLASTIC AGENT; PYRONE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; LEUKEMIA; MICROTUBULE; MOUSE; NONHUMAN; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0031907307     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.2.433     Document Type: Article

References (47)

1. Tomoda H, Nishida H, Kim YK, Obata R, Sunazuka T, Omura S, Bordner J, Guadliana M, Dormer PG and Smith AB: Relative and absolute stereochemistry of pyripyropene A, a potent, bioavailable inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). J Am Chem Soc 116: 12097-12098, 1994.
2. Bell FP: Arterial cholesterol esterification by acyl-CoA:cholesterol acyltransferase: its possible significance in atherogenesis and its inhibition by drugs. In: Pharmacological Control of Hyperlipidaemia. Fears R (ed). J.R. Prous Science Publishers, Barcelona, pp409-422, 1986.
3. Heider JG: Agents which inhibit cholesterol esterification in the intestine and their potential value in the treatment of hypercholesterolaemia. In: Pharmacological Control of Hyperlipidaemia. Fears R (ed). J.R. Prous Science Publishers, Barcelona, pp423-438, 1986.
4. Sliskovic DR and White AD: Therapeutic potential of. ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci 12: 194-199, 1991.
5. Arvanov VL, Ling KH, Chen RC and Tsai MC: Effects of territrem-B on cholinergic responses of snail neuron. Neurosci Lett 152: 69-71, 1993.
6. Lee CY, Ling KH and Wang CT: The effect of territrem A and territrem B on human platelet function. Thromb Haemost 65: 1078, 1991.
7. Ling KH, Yang CK and Peng FT: Territrems, tremorgenic mycotoxins of Aspergillus terreus. Appl Environ Microbiol 37: 355-357, 1979.
8. Ling KH, Liou HH, Yang CM and Yang CK: Isolation, chemical structure, acute toxicity, and some physicochemical properties of territrem C from Aspergillus terrens. Appl Environ Microbiol 47: 98-100, 1984.
9. Omura S, Kuno F, Otoguro K, Sunazuka T, Shiomi K, Masuma R and Iwai Y: Arisugacin, a novel and selective inhibitor of acetylcholinesterase from Penicillium sp. FO-4259. J Antibiot 48: 745-746, 1995.
10. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241-1245, 1986.
11. Hua DH, Chen Y, Sin HS, Maroto MJ, Robinson PD, Newell SW, Perchellet EM, Ladesich JB, Freeman JA, Perchellet JP and Chiang PK: A one-pot condensation of pyrones and enals. Synthesis of 1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyrans. J Organometal Chem 62: 6888-6896, 1997.
12. Perchellet JP, Newell SW, Ladesich JB, Perchellet EM, Chen Y, Hua DH, Kraft SL, Basaraba RJ, Omura S and Tomoda H: Antitumor activity of novel tricyclic pyrone analogs in murine leukemia cells in vitro. Anticancer Res 17: 2427-2434, 1997.
13. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
14. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
15. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
16. Wall ME and Wani MC: Camptothecin and taxol: discovery to clinic. 13th Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 753-760, 1995.
17. Chabner BA and Myers CE: Clinical pharmacology of cancer chemotherapy. In: Cancer Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA (eds). J.B. Lippincott Co, Philadelphia, pp287-328, 1985.
18. Furth JJ and Cohen SS: Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res 28: 2061-2067, 1968.
19. Schrecker AW: Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts. Cancer Res 30: 632-641, 1970.
20. Cohen SS: The lethality of ara nucleotides. Med Biol 54: 299-326, 1976.
21. Chabner BA, Hande KR and Drake JC: Ara-C metabolism: implications for drug resistance and drug interactions. Bull Cancer 66: 89-92, 1979.
22. Krakoff IH: Antimetabolites. In: Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Kuemmerle HP, Berkarda B, Karrer K and Mathé G (eds). Thieme-Stratton, New York, pp187-204, 1984.
23. Erlichman C: The pharmacology of anticancer drugs. In: The Basic Science of Oncology. Tannock IF and Hill RP (eds). Pergamon Press, New York, pp292-307, 1987.
24. Burghardt RC, Barhoumi R, Doolittle DJ and Phillips TD: Application of cellular fluorescence imaging for in vitro toxicology testing. In: Principles and Methods of Toxicology. Hayes AW (ed). Raven Press, New York, pp1231-1258, 1994.
25. Engelborghs Y: Dynamic aspects of microtubule assembly. In: Microtubule Proteins. Avila J (ed). CRC Press, Boca Raton, FL, pp1-35, 1990.
26. Horwitz SB, Chang CK and Grollman AP: Studies on camptothecin: 1. Effects on nucleic acid and protein synthesis. Mol Pharmacol 7:632-644, 1971.
27. Kessel D: Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim Biophys Acta 246: 225-232, 1971.
28. Eisenbrand G, Habs M and Schmähl D: Pharmacology and toxicology of antineoplastic agents. In: Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Kuemmerle HP, Berkarda B, Karrer K and Mathé G (eds). Thieme-Stratton, New York, pp35-91, 1984.
29. Tanaka N: Mode of action of different substances. In: Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Kuemmerle HP, Berkarda B, Karrer K and Mathé G (eds). Thieme-Stratton, New York, pp139-168, 1984.
30. Rosenberg B: Fundamental studies with cisplatin. In: Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy. Kuemmerle HP, Berkarda B, Karrer K and Mathé G (eds). Thieme-Stratton, New York, pp245-263, 1984.
31. Roberts JJ: Molecular mechanisms of action of anti-tumor platinum compounds. In: Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity. Chagas C and Pullman B (eds). Pontifica Academia Scientiarum, Vatican City, pp463-489, 1987.
32. Jones J, Zhen W, Reed E, Parker RJ, Sancar A and Bohr VA: Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266:7101-7107, 1991.
33. Schornagel JH and McVie JG: The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53-75, 1983.
34. Jukes TH: Searching for magic bullets: early approaches to chemotherapy; antifolates, methotrexate. The Bruce F. Cain Memorial Award Lecture. Cancer Res 47: 5528-5536, 1987.
35. Myers CE: The pharmacology of the fluoropyrimidines. Pharmacol Rev 33: 1-15, 1981.
36. Bachur NR: Adriamycin-daunorubicin cellular pharmacodynamics. Biochem Pharmacol 23 (Suppl. 2): 207-216, 1974.
37. Drewinko B and Barlogie B: Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 60: 1295-1306, 1976.
38. Wozniak AJ and Ross WE: DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D- glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43: 120-124, 1983.
39. D'Arpa P and Liu L: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177, 1989.
40. Pommier Y: DNA topoisomerase I and II in cancer chemotherapy: update and perspective. Cancer Chemother Pharmacol 32: 103-108, 1993.
41. Owellen RJ, Owens AH and Donigian DW: The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 47: 685-691, 1972.
42. Owellen RJ, Hartke CA, Dickerson RM and Hains FO: Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36: 1499-1502, 1976.
43. Hamel E: Interaction of tubulin with small ligands. In: Microtubule Proteins. Avila J (ed). CRC Press, Boca Raton, FL, pp89-191, 1990.
44. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
45. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
46. Da Silva CP, de Oliveira CR and da Conceição de Lima M: Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem Pharmacol 51: 1331-1340, 1996.
47. Martin DS and Schwartz GK: Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol Res 9: 1-5, 1997.